Tags

Type your tag names separated by a space and hit enter

Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
Antimicrob Agents Chemother. 2002 Jun; 46(6):1647-50.AA

Abstract

Clostridium difficile is the most frequently identified enteric pathogen in patients with nosocomially acquired, antibiotic-associated diarrhea. The drugs most commonly used to treat diseases associated with C. difficile are metronidazole and vancomycin. Most clinical laboratories assume that all C. difficile isolates are susceptible to metronidazole and vancomycin. We report on the antimicrobial susceptibilities of 415 C. difficile isolates to metronidazole and vancomycin over an 8-year period (1993 to 2000). The overall rate of resistance to metronidazole at the critical breakpoint (16 microg/ml) was 6.3%. Although full resistance to vancomycin was not observed, the overall rate of intermediate resistance was 3.1%. One isolate had a combination of resistance to metronidazole and intermediate resistance to vancomycin. Rates of resistance to metronidazole and vancomycin were higher among isolates from human immunodeficiency virus-infected patients. Molecular typing methods proved the absence of clonality among the isolates with decreased susceptibilities to the antimicrobials tested.

Authors+Show Affiliations

Microbiology and Infectious Diseases Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12019070

Citation

Peláez, T, et al. "Reassessment of Clostridium Difficile Susceptibility to Metronidazole and Vancomycin." Antimicrobial Agents and Chemotherapy, vol. 46, no. 6, 2002, pp. 1647-50.
Peláez T, Alcalá L, Alonso R, et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother. 2002;46(6):1647-50.
Peláez, T., Alcalá, L., Alonso, R., Rodríguez-Créixems, M., García-Lechuz, J. M., & Bouza, E. (2002). Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrobial Agents and Chemotherapy, 46(6), 1647-50.
Peláez T, et al. Reassessment of Clostridium Difficile Susceptibility to Metronidazole and Vancomycin. Antimicrob Agents Chemother. 2002;46(6):1647-50. PubMed PMID: 12019070.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. AU - Peláez,T, AU - Alcalá,L, AU - Alonso,R, AU - Rodríguez-Créixems,M, AU - García-Lechuz,J M, AU - Bouza,E, PY - 2002/5/23/pubmed PY - 2002/10/31/medline PY - 2002/5/23/entrez SP - 1647 EP - 50 JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 46 IS - 6 N2 - Clostridium difficile is the most frequently identified enteric pathogen in patients with nosocomially acquired, antibiotic-associated diarrhea. The drugs most commonly used to treat diseases associated with C. difficile are metronidazole and vancomycin. Most clinical laboratories assume that all C. difficile isolates are susceptible to metronidazole and vancomycin. We report on the antimicrobial susceptibilities of 415 C. difficile isolates to metronidazole and vancomycin over an 8-year period (1993 to 2000). The overall rate of resistance to metronidazole at the critical breakpoint (16 microg/ml) was 6.3%. Although full resistance to vancomycin was not observed, the overall rate of intermediate resistance was 3.1%. One isolate had a combination of resistance to metronidazole and intermediate resistance to vancomycin. Rates of resistance to metronidazole and vancomycin were higher among isolates from human immunodeficiency virus-infected patients. Molecular typing methods proved the absence of clonality among the isolates with decreased susceptibilities to the antimicrobials tested. SN - 0066-4804 UR - https://www.unboundmedicine.com/medline/citation/12019070/Reassessment_of_Clostridium_difficile_susceptibility_to_metronidazole_and_vancomycin_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=12019070 DB - PRIME DP - Unbound Medicine ER -